Login to Your Account

Clinic Roundup

Thursday, August 4, 2011
Trimel Pharmaceuticals Corp., of Toronto, said the FDA accepted its investigational new drug application for its bio-adhesive intranasal gel product development program, TBS-2. The company's TBS-2 product is being developed to treat the subset indication of the female sexual dysfunction anorgasmia. And IND was submitted in June.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription